Merck advances phase 3 trial for islatravir as once-monthly oral PrEP for women at high risk for acquiring HIV-1

This article was originally published here

The study, IMPOWER 22, will evaluate the efficacy and safety of islatravir — Merck’s novel investigational nucleoside reverse transcriptase translocation inhibitor (NRTTI) under evaluation for both treatment and

The post Merck advances phase 3 trial for islatravir as once-monthly oral PrEP for women at high risk for acquiring HIV-1 appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply